3rd Quarter - Report
AKIN GUMP STRAUSS HAUER & FELD for OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
Income
—
Expenses
—
No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Drug Pricing legislation introduced in the 116th Congress; P.L. 115-271, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act implementation; Contract Year (CY) 2020 Medicare Advantage and Part D Drug Pricing Proposed Rule (CMS-4180-P).
| Lobbyist | Covered position, as disclosed |
|---|---|
| LOUIS AGNELLO | — |
| HEIDE BAJNRAUH | — |
| JOHN JONAS | — |
| RICHARD THOMPSON | — |
| MATTHEW TODD TUTEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.